An Early Phase 1 interventional study of [11C]ABBV-112i in Healthy Volunteers, sponsored by AbbVie. Not yet recruiting. Open to participants aged 23 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by AbbVie · Early Phase 1, Interventional, and Basic science
A radioligand is a small amount of a radioactive imaging compound used during a positron emission tomography (PET) scan. This study aims to validate a new positron emission tomography (PET) ligand for measuring M4 receptors in the brain. M4 receptors are proteins that may play a role in various psychiatric and neurological conditions. This study will evaluate the PET ligand [11C]ABBV-112i in healthy adult participants to assess how well the ligand can measure the distribution of the M4 receptors across brain regions and the test-retest variability of the binding measurements.
AbbVie is the lead sponsor of 976 studies on the registry; 135 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 214 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive two single intravenous bolus doses of \[11C\]ABBV-112i, with each dose followed by up to approximately 90 minutes dynamic PET scan.
Drug: [11C]ABBV-112i
Intravenous Bolus
Regional brain volume of distribution (VT) of ABBV-112i across brain regions
VT defined as the ratio of radioligand concentration in the tissue region of interest to that observed in plasma at equilibrium.
Time frame: Up to Approximately Up to Day 1
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.